California State Teachers Retirement System Sells 65,853 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

California State Teachers Retirement System decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 3.2% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 1,984,447 shares of the biopharmaceutical company's stock after selling 65,853 shares during the period. California State Teachers Retirement System owned about 0.16% of Gilead Sciences worth $183,303,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in GILD. HHM Wealth Advisors LLC lifted its position in Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 154 shares during the period. YANKCOM Partnership bought a new position in shares of Gilead Sciences in the 4th quarter worth about $28,000. Decker Retirement Planning Inc. bought a new stake in Gilead Sciences during the fourth quarter worth about $29,000. Crews Bank & Trust purchased a new position in shares of Gilead Sciences during the fourth quarter valued at approximately $31,000. Finally, Stephens Consulting LLC grew its stake in shares of Gilead Sciences by 325.0% in the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock worth $31,000 after buying an additional 260 shares during the last quarter. Institutional investors own 83.67% of the company's stock.

Analyst Ratings Changes

Several research firms have commented on GILD. DZ Bank raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 target price on the stock in a report on Thursday, February 13th. The Goldman Sachs Group raised their price objective on shares of Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a research note on Wednesday, February 12th. Piper Sandler increased their price target on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a report on Wednesday, February 12th. Wells Fargo & Company increased their target price on Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. Finally, Cantor Fitzgerald assumed coverage on Gilead Sciences in a report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price target on the stock. Nine investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, Gilead Sciences presently has an average rating of "Moderate Buy" and a consensus price target of $109.43.

Gilead Sciences Stock Performance

NASDAQ:GILD traded down $3.29 during mid-day trading on Thursday, hitting $103.25. 7,268,702 shares of the company traded hands, compared to its average volume of 7,522,821. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The stock's fifty day moving average price is $109.00 and its 200-day moving average price is $98.58. The firm has a market cap of $128.56 billion, a price-to-earnings ratio of 279.05, a price-to-earnings-growth ratio of 0.71 and a beta of 0.32. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The company had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. During the same period in the previous year, the company posted ($1.32) EPS. The firm's revenue was down .3% on a year-over-year basis. Research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 3.06%. Gilead Sciences's dividend payout ratio (DPR) is presently 66.53%.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $104.09, for a total value of $260,225.00. Following the transaction, the chief financial officer now directly owns 169,061 shares of the company's stock, valued at approximately $17,597,559.49. The trade was a 1.46 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 302,785 shares of company stock worth $30,540,875 in the last three months. Company insiders own 0.27% of the company's stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.